NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
FORT WASHINGTON, Pa., Jan. 15 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) has been awarded a $4 million grant from Wyeth Pharmaceuticals to support clinical studies of temsirolimus (Torisel(R), Wyeth) in the treatment of solid tumors. This is the largest individual research grant that NCCN has received since the inception of its Oncology Research Program in 1999.
Temsirolimus is a targeted therapy approved to treat advanced renal cell carcinoma (RCC), a type of cancer that originates in the kidney. Clinical trials supported by this grant will evaluate the effectiveness of temsirolimus in solid tumors, including but not limited to, breast, endometrial, head and neck, hepatocellular, hormone-refractory prostate, non-small cell lung, and ovarian cancers.
"This grant represents the largest research award to date for NCCN and is an outstanding achievement," says William T. McGivney, PhD, Chief Executive Officer, NCCN. "The funding not only helps accelerate potentially life-saving research in the field of cancer, but also creates a collaborative opportunity for investigators from NCCN Member Institutions. Obtaining major research grants represents yet another way in which NCCN lives out our mission of improving the quality and effectiveness of care provided to patients with cancer."
Temsirolimus is the only commercially available inhibitor of mammalian target of rapamycin (mTOR). The mTOR signaling pathway regulates cell growth and promotes angiogenesis, a physiological process that is a fundamental step in the transition of tumors from a dormant state to a malignant state. By disrupting this pathway, temsirolimus may inhibit the growth of tumors.
"This collaboration represents a unique opportunity to benefit from the research expertise of NCCN and their Member Institutions as we explore the potential of Torisel in the treatment of a variety of solid tumors," says Mikael Dolsten, President, Research and Development, Wyeth Pharmaceuticals. "We are pleased to support an organization that shares our commitment to innovative cancer research to the benefit of patients with cancer."
The primary goal of clinical trials resulting from this grant is to help determine the role of temsirolimus in the treatment of solid tumors in a variety of cancers. Significant secondary goals include:
The NCCN Oncology Research Program (ORP) facilitates all phases of clinical research by identifying clinical investigators and initiating trials at NCCN Member Institutions. The ORP draws on the expertise of investigators at 21 of the world's leading cancer centers and establishes collaborations with pharmaceutical and biotech companies in order to advance therapeutic options for patients with cancer.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the
For more information on NCCN, please visit www.nccn.org.
|SOURCE National Comprehensive Cancer Network|
Copyright©2009 PR Newswire.
All rights reserved